Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn’s disease?

No abstract is available for this paper.

• Publication year

  2013

• Venue

  European Journal of Gastroenterology and Hepathology

• Publication date

  2013-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MEG.0b013e32835d1f15PMID 23337170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

  2012cited by this paper
• PWE-255 5-ASA enhances DUOX2 expression in active ulcerative colitis: a risk for colorectal cancer?

  2012cited by this paper
• Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.

  2012cited by this paper
• Body mass index influences the response to infliximab in ankylosing spondylitis

  2012cited by this paper
• Visceral fat and gut inflammation.

  2012cited by this paper
• Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

  2012cited by this paper
• Adipose Tissue and Inflammatory Bowel Disease Pathogenesis

  2012cited by this paper
• Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

  2012cited by this paper
• Dosage adjustment during long‐term adalimumab treatment for Crohn's disease: Clinical efficacy and pharmacoeconomics

  2011cited by this paper
• Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease?

  2011cited by this paper
• Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

  2011cited by this paper
• A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

  2011cited by this paper
• GI-REASONS: A Novel 6-Month, Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Trial

  2011cited by this paper
• Body mass index and clinical response to infliximab in rheumatoid arthritis.

  2011cited by this paper
• Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

  2011cited by this paper
• Obesity and psoriasis: body weight and body mass index influence the response to biological treatment

  2011cited by this paper
• Proinflammatory cytokines IL-6 and TNF-α and the development of inflammation in obese subjects

  2010cited by this paper
• Effect of Obesity on the Pharmacokinetics of Drugs in Humans

  2010cited by this paper
• Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis: Evidence from the Psocare Project

  2009cited by this paper
• Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis

  2008cited by this paper
• Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data.

  2008cited by this paper
• Obesity, innate immunity and gut inflammation

  2007cited by this paper
• Signalling role of adipose tissue: adipokines and inflammation in obesity.

  2005cited by this paper

• Metabolic Comorbidities and Hospital Outcomes in Patients With Inflammatory Bowel Disease: A Nationwide Analysis.

  2026cites this paper
• Narrative review of adalimumab for the treatment of cardiac sarcoidosis

  2025cites this paper
• Unravelling the Relationship Between Obesity and Inflammatory Bowel Disease

  2025cites this paper
• Body mass index does not influence loss of response to tumor necrosis factor inhibitors in Crohn's disease.

  2025cites this paper
• Reviewing the impact of obesity on inflammatory bowel disease and considerations for optimizing management

  2024cites this paper
• Impact of Obesity and Metabolic Syndrome on IBD Outcomes

  2024cites this paper
• High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn’s Disease

  2024cites this paper
• The importance of predicting patient responses to monoclonal antibodies for Crohn’s disease

  2023cites this paper
• Practical guideline on obesity care in patients with gastrointestinal and liver diseases - Joint ESPEN/UEG guideline.

  2023cites this paper
• The Impact of Obesity on Inflammatory Bowel Disease

  2023cites this paper
• Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease

  2023cites this paper
• Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review

  2023cites this paper
• BMI is important in predicting the loss of response in inflammatory bowel disease patients on tumour necrosis factor-α inhibitors

  2022cites this paper
• Effect of obesity on vedolizumab response in inflammatory bowel disease

  2022cites this paper
• Impact of Obesity on Inflammatory Bowel Disease

  2022influential citation
• Obesity, a challenge in the management of inflammatory bowel diseases

  2022cites this paper
• European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint ESPEN/UEG guideline.

  2022cites this paper
• European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline

  2022cites this paper
• High-fat diet aggravates colitis via mesenteric adipose tissue derived exosome metastasis-associated lung adenocarcinoma transcript 1

  2022cites this paper
• Impact of Obesity on Response to Biologic Therapies in Patients with Inflammatory Bowel Diseases

  2022influential citation
• Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates

  2021cites this paper
• Obesity in inflammatory bowel disease: A review of its role in the pathogenesis, natural history, and treatment of IBD

  2021cites this paper
• Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis

  2021influential citation
• A Comparative Analysis of Drug Therapy, Disease Phenotype, and Health Care Outcomes for Men and Women with Inflammatory Bowel Disease

  2021cites this paper
• Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry

  2020cites this paper
• Associations Between Obesity and the Effectiveness of Anti–Tumor Necrosis Factor-α Agents in Inflammatory Bowel Disease Patients: A Literature Review and Meta-analysis

  2020cites this paper
• Adalimumab Concentration Changes After Dose Escalation in Inflammatory Bowel Disease

  2020cites this paper
• Impact of Obesity on the Management of Inflammatory Bowel Disease.

  2020cites this paper
• Special Indications: Cirrhosis, Inflammatory Bowel Disease, and Organ Transplantation

  2020cites this paper
• Sastav tijela i potrošnja energije u mirovanju bolesnika s upalnim bolestima crijeva na biološkoj terapiji

  2019cites this paper
• Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.

  2019cites this paper
• Application of Pharmacometrics and Systems Pharmacology to Current and Emerging Biologics in Inflammatory Bowel Diseases

  2019cites this paper
• Influence de l’obésité sur l’efficacité de différents agents biologiques dans les maladies inflammatoires : revue systématique et méta-analyse

  2019cites this paper
• The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease.

  2019cites this paper
• Thanks ! Title The changing phenotype of Inflammatory Bowel Disease

  2019cites this paper
• Relationship(s) between obesity and inflammatory bowel diseases: possible intertwined pathogenic mechanisms

  2019cites this paper
• Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study

  2019cites this paper
• High body mass index is not associated with increased treatment failure in infliximab treated pediatric patients with inflammatory bowel disease

  2019cites this paper
• Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn ’ s Disease

  2018cites this paper
• Treatment Failure of TNF-α Inhibitors in Obese Patients With Inflammatory Bowel Disease-A Cohort Study.

  2018cites this paper
• Obesity and Pediatric Drug Development

  2018cites this paper
• Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis

  2018cites this paper
• Obesity and inflammatory bowel disease: diagnostic and therapeutic implications

  2018cites this paper
• Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn’s Disease

  2018cites this paper
• Bariatric Therapy

  2018influential citation
• Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease.

  2018cites this paper
• Review article: the relationship between obesity, bariatric surgery, and inflammatory bowel disease

  2018cites this paper
• Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials

  2018cites this paper
• Endoscopists and Surgeons Playing in the Same Team: The Multidisciplinary Approach in Screening and Preoperative Workup

  2018cites this paper
• An Elevated Body Mass Index is Associated with Lower Serum Adalimumab Levels without Clinical Significance

  2018cites this paper
• Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease.

  2018cites this paper
• Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?

  2018cites this paper
• Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.

  2017cites this paper
• Dose escalation of biologics in Crohn’s disease: critical review of observational studies

  2017cites this paper
• Gastrointestinal Complications of Obesity.

  2017cites this paper
• Comparison of Infliximab and Adalimumab in Biologic‐Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study

  2017cites this paper
• Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes

  2017cites this paper
• Sarcopenia Is Common in Overweight Patients with Inflammatory Bowel Disease and May Predict Need for Surgery

  2017cites this paper
• Extraintestinal Manifestations Are Common in Obese Patients with Crohn's Disease

  2017cites this paper
• Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab

  2017cites this paper
• Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis

  2017cites this paper
• Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels

  2016cites this paper
• Personalized therapy with TNF-inhibitors in Crohn's disease: optimizing treatment outcomes by monitoring drug levels and anti-drug antibodies.

  2016cites this paper
• Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.

  2016cites this paper
• Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies

  2016cites this paper
• The Changing Phenotype of Inflammatory Bowel Disease

  2016cites this paper
• Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease

  2016cites this paper
• Interaction of obesity and inflammatory bowel disease

  2016cites this paper
• Accepted Manuscript Higher Risk of Hospitalization and Serious Infection Among Patients With Ulcerative Colitis Treated with Adalimumab , Compared with Infliximab , in a Nationwide Study

  2016cites this paper
• Weight-based dosing in medication use: what should we know?

  2016cites this paper
• Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease

  2016cites this paper
• Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease.

  2015cites this paper
• Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse

  2015cites this paper
• Nutrition in adult patients with inflammatory bowel disease.

  2014cites this paper
• Pharmacokinetics of biologics and the role of therapeutic monitoring.

  2014cites this paper
• Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study

  2014cites this paper
• Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

  2014cites this paper
• Adipose-Tissue and Intestinal Inflammation – Visceral Obesity and Creeping Fat

  2014cites this paper
• The Increasing Weight of Crohn's Disease Subjects in Clinical Trials: A Hypothesis-generatings Time-trend Analysis

  2013cites this paper